{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:18:53Z","timestamp":1772558333897,"version":"3.50.1"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Sichuan Science and Technology Program of China","award":["2025NSFSC2167"],"award-info":[{"award-number":["2025NSFSC2167"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10822-026-00771-z","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T04:10:39Z","timestamp":1772511039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Computer-aided drug design in acute myeloid leukemia: a comprehensive review of advances, challenges, and future prospect"],"prefix":"10.1007","volume":"40","author":[{"given":"Lu","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tangting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shichan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"3","key":"771_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473646","volume":"45","author":"M Okoniewski","year":"2025","unstructured":"Okoniewski M, Gonzalez Lugo J, Lin TL (2025) Moving away from standard induction in newly diagnosed acute myeloid leukemia. Am Soc Clin Oncol Educ Book 45(3):e473646. https:\/\/doi.org\/10.1200\/EDBK-25-473646","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"771_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","volume":"26","author":"M Wysota","year":"2024","unstructured":"Wysota M, Konopleva M, Mitchell S (2024) Novel therapeutic targets in acute myeloid leukemia (AML). Curr Oncol Rep 26(4):409\u2013420. https:\/\/doi.org\/10.1007\/s11912-024-01503-y","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"771_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01346-1","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Dinardo CD (2025) Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J 15(1):139. https:\/\/doi.org\/10.1038\/s41408-025-01346-1","journal-title":"Blood Cancer J"},{"issue":"3","key":"771_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2021011304","volume":"139","author":"E Estey","year":"2022","unstructured":"Estey E, Hasserjian RP, D\u00f6hner H (2022) Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood 139(3):323\u2013332. https:\/\/doi.org\/10.1182\/blood.2021011304","journal-title":"Blood"},{"issue":"1","key":"771_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01282-2","volume":"21","author":"M Bakhtiyari","year":"2023","unstructured":"Bakhtiyari M, Liaghat M, Aziziyan F, Shapourian H, Yahyazadeh S, Alipour M, Shahveh S, Maleki-Sheikhabadi F, Halimi H, Forghaniesfidvajani R, Zalpoor H, Nabi-Afjadi M, Pornour M (2023) The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways. Cell Commun Signal 21(1):252. https:\/\/doi.org\/10.1186\/s12964-023-01282-2","journal-title":"Cell Commun Signal"},{"issue":"1\u20132","key":"771_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.drup.2012.02.001","volume":"15","author":"BC Shaffer","year":"2012","unstructured":"Shaffer BC, Gillet J-P, Patel C, Baer MR, Bates SE, Gottesman MM (2012) Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat 15(1\u20132):62\u201369. https:\/\/doi.org\/10.1016\/j.drup.2012.02.001","journal-title":"Drug Resist Updat"},{"issue":"9","key":"771_CR7","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1007\/s12272-015-0640-5","volume":"38","author":"SJY Macalino","year":"2015","unstructured":"Macalino SJY, Gosu V, Hong S, Choi S (2015) Role of computer-aided drug design in modern drug discovery. Arch Pharm Res 38(9):1686\u20131701. https:\/\/doi.org\/10.1007\/s12272-015-0640-5","journal-title":"Arch Pharm Res"},{"key":"771_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105675","volume":"121","author":"SC Yen","year":"2022","unstructured":"Yen SC, Chen LC, Huang HL, HuangFu WC, Chen YY, Eight Lin T, Lien ST, Tseng HJ, Sung TY, Hsieh JH, Huang WJ, Pan SL, Hsu KC (2022) Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach. Bioorg Chem 121:105675. https:\/\/doi.org\/10.1016\/j.bioorg.2022.105675","journal-title":"Bioorg Chem"},{"key":"771_CR9","doi-asserted-by":"crossref","unstructured":"Nascimento IJ dos S, de Aquino TM, da Silva-J\u00fanior EF (2022) The new era of drug discovery: the power of computer-aided drug design (CADD). https:\/\/www.ingentaconnect.com\/content\/ben\/lddd\/2022\/00000019\/00000011\/art00002. Accessed 31 Aug 2024","DOI":"10.2174\/1570180819666220405225817"},{"key":"771_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.22270\/jddt.v8i5.1894","volume":"8","author":"S Surabhi","year":"2018","unstructured":"Surabhi S, Singh BK (2018) Computer aided drug design: an overview. J Drug Deliv Ther 8:504\u2013509. https:\/\/doi.org\/10.22270\/jddt.v8i5.1894","journal-title":"J Drug Deliv Ther"},{"issue":"6","key":"771_CR11","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","volume":"4","author":"M Levis","year":"2020","unstructured":"Levis M, Perl AE (2020) Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv 4(6):1178\u20131191. https:\/\/doi.org\/10.1182\/bloodadvances.2019000174","journal-title":"Blood Adv"},{"key":"771_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amolm.2024.100058","volume":"5","author":"U Das","year":"2025","unstructured":"Das U, Chandramouli L, Uttarkar A, Kumar J, Niranjan V (2025) Discovery of natural compounds as novel FMS-like tyrosine kinase-3 (FLT3) therapeutic inhibitors for the treatment of acute myeloid leukemia: an in-silico approach. Asp Mol Med 5:100058. https:\/\/doi.org\/10.1016\/j.amolm.2024.100058","journal-title":"Asp Mol Med"},{"key":"771_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.insi.2025.100006","volume":"1","author":"U Das","year":"2025","unstructured":"Das U, Uttarkar A, Kumar J, Niranjan V (2025) In silico exploration natural compounds for the discovery of novel DNMT3A inhibitors as potential therapeutic agents for acute myeloid leukemia. In Silico Res Biomed 1:100006. https:\/\/doi.org\/10.1016\/j.insi.2025.100006","journal-title":"In Silico Res Biomed"},{"key":"771_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-025-01005-y","volume":"26","author":"U Das","year":"2025","unstructured":"Das U, Mukherjee A, Mukunthan KS, Kumar J (2025) Identification of potential natural BCL-2 inhibitors for leukemia through an integrated virtual screening approach. BMC Pharmacol Toxicol 26:176. https:\/\/doi.org\/10.1186\/s40360-025-01005-y","journal-title":"BMC Pharmacol Toxicol"},{"key":"771_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106324","volume":"181","author":"D Vemula","year":"2023","unstructured":"Vemula D, Jayasurya P, Sushmitha V, Kumar YN, Bhandari V (2023) CADD, AI and ML in drug discovery: a comprehensive review. Eur J Pharm Sci 181:106324. https:\/\/doi.org\/10.1016\/j.ejps.2022.106324","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"771_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1042\/BST20211240","volume":"50","author":"JW Lee","year":"2022","unstructured":"Lee JW, Maria-Solano MA, Vu TNL, Yoon S, Choi S (2022) Big data and artificial intelligence (AI) methodologies for computer-aided drug design (CADD). Biochem Soc Trans 50(1):241\u2013252. https:\/\/doi.org\/10.1042\/BST20211240","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"771_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/bib\/bbz157","volume":"22","author":"M Bagherian","year":"2021","unstructured":"Bagherian M, Sabeti E, Wang K, Sartor MA, Nikolovska-Coleska Z, Najarian K (2021) Machine learning approaches and databases for prediction of drug\u2013target interaction: a survey paper. Brief Bioinform 22(1):247\u2013269. https:\/\/doi.org\/10.1093\/bib\/bbz157","journal-title":"Brief Bioinform"},{"key":"771_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2025.100213","volume":"27","author":"U Das","year":"2025","unstructured":"Das U (2025) Generative AI for drug discovery and protein design: the next frontier in AI-driven molecular science. Med Drug Discov 27:100213. https:\/\/doi.org\/10.1016\/j.medidd.2025.100213","journal-title":"Med Drug Discov"},{"key":"771_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202502448","volume":"10","author":"U Das","year":"2025","unstructured":"Das U (2025) Transforming precision medicine through generative AI: advanced architectures and tailored therapeutic design for patient-specific drug discovery. Chem Select 10:e02448. https:\/\/doi.org\/10.1002\/slct.202502448","journal-title":"Chem Select"},{"issue":"1","key":"771_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","volume":"31","author":"K Zhang","year":"2025","unstructured":"Zhang K, Yang X, Wang Y, Yu Y, Huang N, Huang N, Li X, Wu JC, Yang S (2025) Artificial intelligence in drug development. Nat Med 31(1):45\u201359. https:\/\/doi.org\/10.1038\/s41591-024-03434-4","journal-title":"Nat Med"},{"key":"771_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2174\/1570180819666220922103109","volume":"21","author":"MT Muhammed","year":"2024","unstructured":"Muhammed MT, Aki-Yalcin E (2024) Molecular docking: principles, advances, and its applications in drugdiscovery. LDDD 21:480\u2013495. https:\/\/doi.org\/10.2174\/1570180819666220922103109","journal-title":"LDDD"},{"issue":"1","key":"771_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/17460441.2018.1403419","volume":"13","author":"X Liu","year":"2018","unstructured":"Liu X, Shi D, Zhou S, Liu H, Liu H, Yao X (2018) Molecular dynamics simulations and novel drug discovery. Expert Opin Drug Discov 13(1):23\u201337. https:\/\/doi.org\/10.1080\/17460441.2018.1403419","journal-title":"Expert Opin Drug Discov"},{"issue":"5","key":"771_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/bib\/bbp023","volume":"10","author":"CM Song","year":"2009","unstructured":"Song CM, Lim SJ, Tong JC (2009) Recent advances in computer-aided drug design. Brief Bioinform 10(5):579\u2013591. https:\/\/doi.org\/10.1093\/bib\/bbp023","journal-title":"Brief Bioinform"},{"key":"771_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12982-024-00229-3","volume":"21","author":"RBO Ouma","year":"2024","unstructured":"Ouma RBO, Ngari SM, Kibet JK (2024) A review of the current trends in computational approaches in drug design and metabolism. Discov Public Health 21:108. https:\/\/doi.org\/10.1186\/s12982-024-00229-3","journal-title":"Discov Public Health"},{"key":"771_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-4939-6634-9_5","volume":"1520","author":"W Yu","year":"2017","unstructured":"Yu W, MacKerell AD (2017) Computer-aided drug design methods. Methods Mol Biol 1520:85\u2013106. https:\/\/doi.org\/10.1007\/978-1-4939-6634-9_5","journal-title":"Methods Mol Biol"},{"issue":"10","key":"771_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/1062936X.2019.1659412","volume":"30","author":"A Sulimov","year":"2019","unstructured":"Sulimov A, Kutov D, Ilin I, Zheltkov D, Tyrtyshnikov E, Sulimov V (2019) Supercomputer docking with a large number of degrees of freedom. SAR QSAR Environ Res 30(10):733\u2013749. https:\/\/doi.org\/10.1080\/1062936X.2019.1659412","journal-title":"SAR QSAR Environ Res"},{"key":"771_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2174\/1570180819666220408133643","volume":"19","author":"MT Muhammed","year":"2022","unstructured":"Muhammed MT, Kuyucuklu G, Kaynak-Onurdag F, Aki-Yalcin E (2022) Synthesis, antimicrobial activity, and molecular modeling studies of some benzoxazole derivatives. LDDD 19:757\u2013768. https:\/\/doi.org\/10.2174\/1570180819666220408133643","journal-title":"LDDD"},{"issue":"7","key":"771_CR28","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"LG Ferreira","year":"2015","unstructured":"Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD (2015) Molecular docking and structure-based drug design strategies. Molecules 20(7):13384\u201313421. https:\/\/doi.org\/10.3390\/molecules200713384","journal-title":"Molecules"},{"issue":"6294","key":"771_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/347631a0","volume":"347","author":"M Karplus","year":"1990","unstructured":"Karplus M, Petsko GA (1990) Molecular dynamics simulations in biology. Nature 347(6294):631\u2013639. https:\/\/doi.org\/10.1038\/347631a0","journal-title":"Nature"},{"issue":"18","key":"771_CR30","doi-asserted-by":"publisher","first-page":"12964","DOI":"10.1039\/c6cp01555g","volume":"18","author":"Z Wang","year":"2016","unstructured":"Wang Z, Sun H, Yao X, Li D, Xu L, Li Y, Tian S, Hou T (2016) Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: the prediction accuracy of sampling power and scoring power. Phys Chem Chem Phys 18(18):12964\u201312975. https:\/\/doi.org\/10.1039\/c6cp01555g","journal-title":"Phys Chem Chem Phys"},{"issue":"20","key":"771_CR31","doi-asserted-by":"publisher","first-page":"7731","DOI":"10.1039\/c3cp00116d","volume":"15","author":"F Godschalk","year":"2013","unstructured":"Godschalk F, Genheden S, S\u00f6derhjelm P, Ryde U (2013) Comparison of MM\/GBSA calculations based on explicit and implicit solvent simulations. Phys Chem Chem Phys 15(20):7731\u20137739. https:\/\/doi.org\/10.1039\/c3cp00116d","journal-title":"Phys Chem Chem Phys"},{"issue":"7","key":"771_CR32","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1039\/c7md00184c","volume":"8","author":"C Pu","year":"2017","unstructured":"Pu C, Yan G, Shi J, Li R (2017) Assessing the performance of docking scoring function, FEP, MM-GBSA, and QM\/MM-GBSA approaches on a series of PLK1 inhibitors. Medchemcomm 8(7):1452\u20131458. https:\/\/doi.org\/10.1039\/c7md00184c","journal-title":"Medchemcomm"},{"issue":"39","key":"771_CR33","doi-asserted-by":"publisher","first-page":"12537","DOI":"10.1021\/jp802648k","volume":"112","author":"M Kaukonen","year":"2008","unstructured":"Kaukonen M, S\u00f6derhjelm P, Heimdal J, Ryde U (2008) QM\/MM\u2212PBSA method to estimate free energies for reactions in proteins. J Phys Chem B 112(39):12537\u201312548. https:\/\/doi.org\/10.1021\/jp802648k","journal-title":"J Phys Chem B"},{"issue":"3","key":"771_CR34","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1021\/acs.jctc.7b01195","volume":"14","author":"L Shen","year":"2018","unstructured":"Shen L, Yang W (2018) Molecular dynamics simulations with quantum mechanics\/molecular mechanics and adaptive neural networks. J Chem Theory Comput 14(3):1442\u20131455. https:\/\/doi.org\/10.1021\/acs.jctc.7b01195","journal-title":"J Chem Theory Comput"},{"issue":"8","key":"771_CR35","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.drudis.2016.06.013","volume":"21","author":"Danishuddin","year":"2016","unstructured":"Danishuddin, Khan AU (2016) Descriptors and their selection methods in QSAR analysis: paradigm for drug design. Drug Discov Today 21(8):1291\u20131302. https:\/\/doi.org\/10.1016\/j.drudis.2016.06.013","journal-title":"Drug Discov Today"},{"issue":"2","key":"771_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/157340607780059521","volume":"3","author":"S Khedkar","year":"2007","unstructured":"Khedkar S, Malde A, Coutinho E, Srivastava S (2007) Pharmacophore modeling in drug discovery and development: an overview. Med Chem 3(2):187\u2013197. https:\/\/doi.org\/10.2174\/157340607780059521","journal-title":"Med Chem"},{"issue":"11\u201312","key":"771_CR37","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","volume":"15","author":"SY Yang","year":"2010","unstructured":"Yang SY (2010) Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 15(11\u201312):444\u2013450. https:\/\/doi.org\/10.1016\/j.drudis.2010.03.013","journal-title":"Drug Discov Today"},{"issue":"9","key":"771_CR38","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.drudis.2020.07.005","volume":"25","author":"L Zhao","year":"2020","unstructured":"Zhao L, Ciallella HL, Aleksunes LM, Zhu H (2020) Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling. Drug Discov Today 25(9):1624\u20131638. https:\/\/doi.org\/10.1016\/j.drudis.2020.07.005","journal-title":"Drug Discov Today"},{"issue":"7792","key":"771_CR39","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41586-019-1923-7","volume":"577","author":"AW Senior","year":"2020","unstructured":"Senior AW, Evans R, Jumper J, Kirkpatrick J, Sifre L, Green T, Qin C, \u017d\u00eddek A, Nelson AWR, Bridgland A, Penedones H, Petersen S, Simonyan K, Crossan S, Kohli P, Jones DT, Silver D, Kavukcuoglu K, Hassabis D (2020) Improved protein structure prediction using potentials from deep learning. Nature 577(7792):706\u2013710. https:\/\/doi.org\/10.1038\/s41586-019-1923-7","journal-title":"Nature"},{"key":"771_CR40","doi-asserted-by":"publisher","DOI":"10.34133\/jbioxresearch.0041","volume":"8","author":"S Roy","year":"2025","unstructured":"Roy S, Nagaraj K, Mittal A (2025) Artificial intelligence in virtual screening: transforming drug research and discovery\u2014a review. J Bio-X Res 8:0041. https:\/\/doi.org\/10.34133\/jbioxresearch.0041","journal-title":"J Bio-X Res"},{"issue":"2","key":"771_CR41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1039\/D4DD00311J","volume":"4","author":"R \u00d6z\u00e7elik","year":"2025","unstructured":"\u00d6z\u00e7elik R, Grisoni F (2025) A hitchhiker\u2019s guide to deep chemical language processing for bioactivity prediction. Digit Discov 4(2):316\u2013325. https:\/\/doi.org\/10.1039\/D4DD00311J","journal-title":"Digit Discov"},{"key":"771_CR42","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1477870\/v1","volume":"7","author":"X Zeng","year":"2022","unstructured":"Zeng X, Xiang H, Yu L, Wang J, Li K, Nussinov R, Cheng F (2022) Accurate prediction of molecular targets using a self-supervised image representation learning framework. Res Sq 7:rs.3.rs-1477870. https:\/\/doi.org\/10.21203\/rs.3.rs-1477870\/v1","journal-title":"Res Sq"},{"issue":"46","key":"771_CR43","doi-asserted-by":"publisher","first-page":"31357","DOI":"10.1021\/jacs.4c11686","volume":"146","author":"O Zhang","year":"2024","unstructured":"Zhang O, Lin H, Zhang H, Huang Y, Hsieh CY, Pan P, Hou T (2024) Deep lead optimization: leveraging generative AI for structural modification. J Am Chem Soc 146(46):31357\u201331370. https:\/\/doi.org\/10.1021\/jacs.4c11686","journal-title":"J Am Chem Soc"},{"key":"771_CR44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s42256-025-00993-0","volume":"7","author":"S Gu","year":"2025","unstructured":"Gu S, Shen C, Zhang X, Sun H, Cai H, Luo H, Zhao H, Liu B, Du H, Zhao Y, Fu C et al (2025) Benchmarking AI-powered docking methods from the perspective of virtual screening. Nat Mach Intell 7:509\u2013520. https:\/\/doi.org\/10.1038\/s42256-025-00993-0","journal-title":"Nat Mach Intell"},{"issue":"2","key":"771_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-023-00832-0","volume":"23","author":"A Tropsha","year":"2024","unstructured":"Tropsha A, Isayev O, Varnek A, Schneider G, Cherkasov A (2024) Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR. Nat Rev Drug Discov 23(2):141\u2013155. https:\/\/doi.org\/10.1038\/s41573-023-00832-0","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"771_CR46","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2024.13353","volume":"30","author":"AS Carranza-Aranda","year":"2024","unstructured":"Carranza-Aranda AS, Jave-Su\u00e1rez LF, Flores-Hern\u00e1ndez FY, Huizar-L\u00f3pez MDR, Huizar-L\u00f3pez MDR, Santerre A (2024) In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia. Mol Med Rep 30(6):229. https:\/\/doi.org\/10.3892\/mmr.2024.13353","journal-title":"Mol Med Rep"},{"issue":"12","key":"771_CR47","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","volume":"90","author":"M Carroll","year":"1997","unstructured":"Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ (1997) CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90(12):4947\u20134952","journal-title":"Blood"},{"issue":"12","key":"771_CR48","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3390\/ph18121793","volume":"18","author":"K-S Park","year":"2025","unstructured":"Park K-S, Jeon M (2025) Advancing PROTAC discovery through artificial intelligence: opportunities, challenges, and future directions. Pharmaceuticals 18(12):1793. https:\/\/doi.org\/10.3390\/ph18121793","journal-title":"Pharmaceuticals"},{"key":"771_CR49","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s42256-022-00527-y","volume":"4","author":"S Zheng","year":"2022","unstructured":"Zheng S, Tan Y, Wang Z, Li C, Zhang Z, Sang X (2022) Accelerated rational PROTAC design via deep learning and molecular simulations. Nat Mach Intell 4:739\u2013748. https:\/\/doi.org\/10.1038\/s42256-022-00527-y","journal-title":"Nat Mach Intell"},{"issue":"5","key":"771_CR50","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM (2025) Acute Myeloid Leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol 100(5):860\u2013891. https:\/\/doi.org\/10.1002\/ajh.27625","journal-title":"Am J Hematol"},{"issue":"1","key":"771_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, Kadia T, Sasaki K, Short NJ, Yilmaz M, Ravandi F (2024) Current status and research directions in acute myeloid leukemia. Blood Cancer J 14(1):163. https:\/\/doi.org\/10.1038\/s41408-024-01143-2","journal-title":"Blood Cancer J"},{"issue":"2","key":"771_CR52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ (2019) Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33(2):299\u2013312. https:\/\/doi.org\/10.1038\/s41375-018-0357-9","journal-title":"Leukemia"},{"issue":"20","key":"771_CR53","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.3390\/jcm12206429","volume":"12","author":"C Negotei","year":"2023","unstructured":"Negotei C, Negotei C, Mitu I, Lupu AR, Lapadat ME, Popovici CE, Crainicu M, Stanca O, Berbec NM (2023) A review of FLT3 kinase inhibitors in AML. J Clin Med 12(20):6429. https:\/\/doi.org\/10.3390\/jcm12206429","journal-title":"J Clin Med"},{"issue":"10","key":"771_CR54","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","volume":"132","author":"M Konopleva","year":"2018","unstructured":"Konopleva M, Letai A (2018) BCL-2 inhibition in AML: an unexpected bonus? Blood 132(10):1007\u20131012. https:\/\/doi.org\/10.1182\/blood-2018-03-828269","journal-title":"Blood"},{"issue":"2","key":"771_CR55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","volume":"32","author":"VA Guerra","year":"2019","unstructured":"Guerra VA, DiNardo C, Konopleva M (2019) Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol 32(2):145\u2013153. https:\/\/doi.org\/10.1016\/j.beha.2019.05.008","journal-title":"Best Pract Res Clin Haematol"},{"issue":"21","key":"771_CR56","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.3390\/jcm10215096","volume":"10","author":"M Tiribelli","year":"2021","unstructured":"Tiribelli M, Michelutti A, Cavallin M, Di Giusto S, Simeone E, Fanin R, Damiani D (2021) BCL-2 expression in AML patients over 65 years: impact on outcomes across different therapeutic strategies. J Clin Med 10(21):5096. https:\/\/doi.org\/10.3390\/jcm10215096","journal-title":"J Clin Med"},{"issue":"1","key":"771_CR57","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2196482","volume":"28","author":"MZ Mohamed Jiffry","year":"2023","unstructured":"Mohamed Jiffry MZ, Kloss R, Ahmed-Khan M, Carmona-Pires F, Okam N, Weeraddana P, Dharmaratna D, Dandwani M, Moin K (2023) A review of treatment options employed in relapsed\/refractory AML. Hematology 28(1):2196482. https:\/\/doi.org\/10.1080\/16078454.2023.2196482","journal-title":"Hematology"},{"issue":"19","key":"771_CR58","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1182\/bloodadvances.2022008282","volume":"7","author":"S Zarnegar-Lumley","year":"2023","unstructured":"Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O\u2019Dwyer K, Tallman MS, Litzow M, Atallah E, Cooper TM, Aplenc RA, Abdel-Wahab O, Gamis AS, Luger S, Erba H, Levine R, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K (2023) Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Adv 7(19):5941\u20135953. https:\/\/doi.org\/10.1182\/bloodadvances.2022008282","journal-title":"Blood Adv"},{"issue":"3","key":"771_CR59","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/sj.leu.2401694","volume":"14","author":"D Ross","year":"2000","unstructured":"Ross D (2000) Novel mechanisms of drug resistance in leukemia. Leukemia 14(3):467\u2013473. https:\/\/doi.org\/10.1038\/sj.leu.2401694","journal-title":"Leukemia"},{"issue":"1","key":"771_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S (2023) Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther 8(1):262. https:\/\/doi.org\/10.1038\/s41392-023-01469-6","journal-title":"Signal Transduct Target Ther"},{"key":"771_CR61","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","volume":"67","author":"CA Ramos","year":"2016","unstructured":"Ramos CA, Heslop HE, Brenner MK (2016) CAR-T cell therapy for lymphoma. Annu Rev Med 67:165\u2013183. https:\/\/doi.org\/10.1146\/annurev-med-051914-021702","journal-title":"Annu Rev Med"},{"issue":"1","key":"771_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"H Li","year":"2020","unstructured":"Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X (2020) Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther 5(1):1. https:\/\/doi.org\/10.1038\/s41392-019-0089-y","journal-title":"Signal Transduct Target Ther"},{"issue":"18","key":"771_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241813953","volume":"24","author":"L Li","year":"2023","unstructured":"Li L, Liu S, Wang B, Liu F, Xu S, Li P, Chen Y (2023) An updated review on developing small molecule kinase inhibitors using computer-aided drug design approaches. Int J Mol Sci 24(18):13953. https:\/\/doi.org\/10.3390\/ijms241813953","journal-title":"Int J Mol Sci"},{"issue":"2","key":"771_CR64","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1021\/ml2002423","volume":"3","author":"MJ Munchhof","year":"2011","unstructured":"Munchhof MJ, Li Q, Shavnya A, Borzillo GV, Boyden TL, Jones CS, LaGreca SD, Martinez-Alsina L, Patel N, Pelletier K, Reiter LA, Robbins MD, Tkalcevic GT (2011) Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med Chem Lett 3(2):106\u2013111. https:\/\/doi.org\/10.1021\/ml2002423","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"771_CR65","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","volume":"9","author":"J Popovici-Muller","year":"2018","unstructured":"Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G et al (2018) Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 9(4):300\u2013305. https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00421","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"771_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00536-7","volume":"18","author":"J Chen","year":"2020","unstructured":"Chen J, Yang J, Wei Q, Weng L, Wu F, Shi Y, Cheng X, Cai X, Hu C, Cao P (2020) Identification of a selective inhibitor of IDH2\/R140Q enzyme that induces cellular differentiation in leukemia cells. Cell Commun Signal 18(1):55. https:\/\/doi.org\/10.1186\/s12964-020-00536-7","journal-title":"Cell Commun Signal"},{"issue":"2","key":"771_CR67","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL et al (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202\u2013208. https:\/\/doi.org\/10.1038\/nm.3048","journal-title":"Nat Med"},{"issue":"5","key":"771_CR68","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","volume":"35","author":"M Mori","year":"2017","unstructured":"Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, Shimada I, Mori K, Kuromitsu S (2017) Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs 35(5):556\u2013565. https:\/\/doi.org\/10.1007\/s10637-017-0470-z","journal-title":"Invest New Drugs"},{"issue":"4","key":"771_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121177","volume":"10","author":"JA Zorn","year":"2015","unstructured":"Zorn JA, Wang Q, Fujimura E, Barros T, Kuriyan J (2015) Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220). PLoS ONE 10(4):e0121177. https:\/\/doi.org\/10.1371\/journal.pone.0121177","journal-title":"PLoS ONE"},{"issue":"1","key":"771_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu H (2021) Emerging agents and regimens for AML. J Hematol Oncol 14(1):49. https:\/\/doi.org\/10.1186\/s13045-021-01062-w","journal-title":"J Hematol Oncol"},{"key":"771_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.972606","volume":"12","author":"R Wang","year":"2022","unstructured":"Wang R, Xu P, Chang LL, Zhang SZ, Zhu HH (2022) Targeted therapy in NPM1-mutated AML: knowns and unknowns. Front Oncol 12:972606. https:\/\/doi.org\/10.3389\/fonc.2022.972606","journal-title":"Front Oncol"},{"issue":"7863","key":"771_CR72","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nature24678","volume":"552","author":"I Barbieri","year":"2017","unstructured":"Barbieri I, Tzelepis K, Pandolfini L, Shi J, Mill\u00e1n-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister AJ, Han N, De Braekeleer E, Ponstingl H, Hendrick A, Vakoc CR, Vassiliou GS, Kouzarides T (2017) Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature 552(7863):126\u2013131. https:\/\/doi.org\/10.1038\/nature24678","journal-title":"Nature"},{"issue":"7860","key":"771_CR73","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG, Webster NA, Andrews B, Fosbeary R, Guest P, Irigoyen N, Eleftheriou M et al (2021) Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593(7860):597\u2013601. https:\/\/doi.org\/10.1038\/s41586-021-03536-w","journal-title":"Nature"},{"issue":"3","key":"771_CR74","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1021\/acs.jmedchem.4c02225","volume":"68","author":"G Dutheuil","year":"2025","unstructured":"Dutheuil G, Oukoloff K, Korac J, Lenoir F, El Bousmaqui M, Probst N, Lapin A, Nakhabina G, Sorlet C, Parmentier N, Karila D, Ghavtadze N et al (2025) Discovery, optimization, and preclinical pharmacology of EP652, a METTL3 inhibitor with efficacy in liquid and solid tumor models. J Med Chem 68(3):2981\u20133003. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02225","journal-title":"J Med Chem"},{"issue":"9","key":"771_CR75","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1039\/d5md00359h","volume":"16","author":"AC Weldert","year":"2025","unstructured":"Weldert AC, Frey AF, Krone MW, Kr\u00e4he F, Kuhn H, Kersten C, Barthels F (2025) Structure-guided design of a methyltransferase-like 3 (METTL3) proteolysis targeting chimera (PROTAC) incorporating an indole-nicotinamide chemotype. RSC Med Chem 16(9):4194\u20134207. https:\/\/doi.org\/10.1039\/d5md00359h","journal-title":"RSC Med Chem"},{"issue":"1","key":"771_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s42004-023-01019-9","volume":"6","author":"GA Ross","year":"2023","unstructured":"Ross GA, Lu C, Scarabelli G, Albanese SK, Houang E, Abel R, Harder ED, Wang L (2023) The maximal and current accuracy of rigorous protein-ligand binding free energy calculations. Commun Chem 6(1):222. https:\/\/doi.org\/10.1038\/s42004-023-01019-9","journal-title":"Commun Chem"},{"issue":"10","key":"771_CR77","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, Wong K, Pathuri S, Briand J, Steidel M, Chapman P, Groy A, Wiseman AK, McHugh CF et al (2021) Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer 2(10):1002\u20131017","journal-title":"Nat Cancer"},{"issue":"3","key":"771_CR78","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00277-024-05885-8","volume":"104","author":"G Huang","year":"2025","unstructured":"Huang G, Cai X, Li D (2025) Significance of targeting DNMT3A mutations in AML. Ann Hematol 104(3):1399\u20131414. https:\/\/doi.org\/10.1007\/s00277-024-05885-8","journal-title":"Ann Hematol"},{"issue":"24","key":"771_CR79","doi-asserted-by":"publisher","first-page":"12931","DOI":"10.1039\/c9cp02024a","volume":"21","author":"T Xie","year":"2019","unstructured":"Xie T, Yu J, Fu W, Wang Z, Xu L, Chang S, Wang E, Zhu F, Zeng S, Kang Y, Hou T (2019) Insight into the selective binding mechanism of DNMT1 and DNMT3A inhibitors: a molecular simulation study. Phys Chem Chem Phys 21(24):12931\u201312947. https:\/\/doi.org\/10.1039\/c9cp02024a","journal-title":"Phys Chem Chem Phys"},{"issue":"1","key":"771_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-64236-9","volume":"14","author":"G Kudo","year":"2024","unstructured":"Kudo G, Hirao T, Harada R, Hirokawa T, Shigeta Y, Yoshino R (2024) Prediction of the binding mechanism of a selective DNA methyltransferase 3A inhibitor by molecular simulation. Sci Rep 14(1):13508. https:\/\/doi.org\/10.1038\/s41598-024-64236-9","journal-title":"Sci Rep"},{"issue":"11","key":"771_CR81","doi-asserted-by":"publisher","first-page":"10704","DOI":"10.1021\/acs.jmedchem.4c02075","volume":"68","author":"F Calzaferri","year":"2025","unstructured":"Calzaferri F, Daher H, Gilbert J, Yang Y, Tauziet M, Jallet C, Bessin Y, Bessin Y, Arimondo PB, Krimm I, Julien E, Lopez M (2025) Rational design and synthesis of highly stable haloflavanone DNA methyltransferase inhibitors inducing tumor suppressor gene re-expression in cancer cells. J Med Chem 68(11):10704\u201310721. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02075","journal-title":"J Med Chem"},{"issue":"16","key":"771_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612652","volume":"24","author":"W Yang","year":"2023","unstructured":"Yang W, Zhuang J, Li C, Bai C, Cheng G (2023) Insights into the inhibitory mechanisms of the covalent drugs for DNMT3A. Int J Mol Sci 24(16):12652. https:\/\/doi.org\/10.3390\/ijms241612652","journal-title":"Int J Mol Sci"},{"issue":"4","key":"771_CR83","doi-asserted-by":"publisher","DOI":"10.1007\/s00894-023-05516-5","volume":"29","author":"AR Issahaku","year":"2023","unstructured":"Issahaku AR, Mncube SM, Agoni C, Kwofie SK, Alahmdi MI, Abo-Dya NE, Sidhom PA, Sidhom PA, Ibrahim MAA, Mukelabai N, Soremekun O, Soliman MES (2023) Multi-dimensional structural footprint identification for the design of potential scaffolds targeting METTL3 in cancer treatment from natural compounds. J Mol Model 29(4):122. https:\/\/doi.org\/10.1007\/s00894-023-05516-5","journal-title":"J Mol Model"},{"key":"771_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117945","volume":"297","author":"D Luo","year":"2025","unstructured":"Luo D, Zhang M, Liang Z, Gan L, He Y, Zhang SL (2025) Discovery and structure-activity relationship study of novel hydantoin-based inhibitors targeting mutant isocitrate dehydrogenase 1 (mIDH1). Eur J Med Chem 297:117945. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117945","journal-title":"Eur J Med Chem"},{"issue":"4","key":"771_CR85","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1021\/acsmedchemlett.4c00634","volume":"16","author":"X Chi","year":"2025","unstructured":"Chi X, Chen R, Yang X, He X, Pan Z, Yao C, Peng H, Yang H, Huang W, Chen Z (2025) Discovery of novel DDR1 inhibitors through a hybrid virtual screening pipeline, biological evaluation and molecular dynamics simulations. ACS Med Chem Lett 16(4):602\u2013610. https:\/\/doi.org\/10.1021\/acsmedchemlett.4c00634","journal-title":"ACS Med Chem Lett"},{"key":"771_CR86","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1182\/blood-2023-178258","volume":"142","author":"JX Cheng","year":"2023","unstructured":"Cheng JX, Wood S, Tang D (2023) Overcoming Venetoclax resistance in leukemia with AI-designed RNA epigenetic inhibitors. Blood 142:5738. https:\/\/doi.org\/10.1182\/blood-2023-178258","journal-title":"Blood"},{"issue":"12","key":"771_CR87","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1021\/jm4004285","volume":"57","author":"A Cherkasov","year":"2014","unstructured":"Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M, Dearden J, Gramatica P, Martin YC, Todeschini R, Consonni V, Kuz\u2019min VE, Cramer R, Benigni R, Yang C, Rathman J, Terfloth L, Gasteiger J, Richard A, Tropsha A (2014) QSAR modeling: where have you been? Where are you going to? J Med Chem 57(12):4977\u20135010. https:\/\/doi.org\/10.1021\/jm4004285","journal-title":"J Med Chem"},{"issue":"10","key":"771_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013543","volume":"5","author":"DB Rosen","year":"2010","unstructured":"Rosen DB, Minden MD, Kornblau SM, Cohen A, Gayko U, Putta S, Woronicz J, Evensen E, Fantl WJ, Cesano A (2010) Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS ONE 5(10):e13543. https:\/\/doi.org\/10.1371\/journal.pone.0013543","journal-title":"PLoS ONE"},{"key":"771_CR89","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jmgm.2019.01.011","volume":"88","author":"RF Abutayeh","year":"2019","unstructured":"Abutayeh RF, Taha MO (2019) Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods. J Mol Graph Model 88:128\u2013151. https:\/\/doi.org\/10.1016\/j.jmgm.2019.01.011","journal-title":"J Mol Graph Model"},{"issue":"22","key":"771_CR90","doi-asserted-by":"publisher","first-page":"12511","DOI":"10.3390\/ijms222212511","volume":"22","author":"S Ghosh","year":"2021","unstructured":"Ghosh S, Ghosh S, Cho SJ (2021) Molecular modeling studies of n-phenylpyrimidine-4-amine derivatives for inhibiting FMS-like tyrosine kinase-3. Int J Mol Sci 22(22):12511. https:\/\/doi.org\/10.3390\/ijms222212511","journal-title":"Int J Mol Sci"},{"issue":"1","key":"771_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/ph18010096","volume":"18","author":"JJ Alc\u00e1zar","year":"2025","unstructured":"Alc\u00e1zar JJ, Alc\u00e1zar JJ, Merino C, Monasterio B, Sajuria G, Miranda D, D\u00edaz F, Campod\u00f3nico PR (2025) A simple machine learning-based quantitative structure-activity relationship model for predicting pIC50 inhibition values of FLT3 tyrosine kinase. Pharmaceuticals 18(1):96. https:\/\/doi.org\/10.3390\/ph18010096","journal-title":"Pharmaceuticals"},{"key":"771_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117089","volume":"282","author":"D Chu","year":"2025","unstructured":"Chu D, Ji C, Zhang Y, Wei C, Zhang X, Zhong Q, Yan H, Wang J (2025) Identification of inhibitors targeting the FLT3-ITD mutation through 4D-QSAR, in vitro, and in silico. Eur J Med Chem 282:117089. https:\/\/doi.org\/10.1016\/j.ejmech.2024.117089","journal-title":"Eur J Med Chem"},{"issue":"2","key":"771_CR93","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.canlet.2014.03.013","volume":"347","author":"Q Wu","year":"2014","unstructured":"Wu Q, Yang Z, Nie Y, Shi Y, Fan D (2014) Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett 347(2):159\u2013166. https:\/\/doi.org\/10.1016\/j.canlet.2014.03.013","journal-title":"Cancer Lett"},{"key":"771_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s44386-024-00001-2","volume":"1","author":"H Wei","year":"2024","unstructured":"Wei H, McCammon JA (2024) Structure and dynamics in drug discovery. npj Drug Discov 1:1. https:\/\/doi.org\/10.1038\/s44386-024-00001-2","journal-title":"npj Drug Discov"},{"key":"771_CR95","unstructured":"EHA Library (2021) Frequency of FLT3-ITD and FLT3-TKD mutations in patients with acute myeloid leukemia: a systematic literature review and meta-analysis. Lewis J https:\/\/library.ehaweb.org\/eha\/2021\/eha2021-virtual-congress\/324086\/juliana.lewis.frequency.of.flt3-itd.and.flt3-tkd.mutations.in.patients.with.html. Accessed 19 Jan 2026"},{"issue":"8","key":"771_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8080245","volume":"8","author":"M Eguchi","year":"2020","unstructured":"Eguchi M, Eguchi M, Kuzume A, Chi S (2020) Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia. Biomedicines 8(8):245. https:\/\/doi.org\/10.3390\/biomedicines8080245","journal-title":"Biomedicines"},{"issue":"18","key":"771_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184573","volume":"15","author":"TJL Lang","year":"2023","unstructured":"Lang TJL, Damm F, Damm F, Frick M (2023) Mechanisms of resistance to small molecules in acute myeloid leukemia. Cancers 15(18):4573. https:\/\/doi.org\/10.3390\/cancers15184573","journal-title":"Cancers"},{"issue":"19","key":"771_CR98","doi-asserted-by":"publisher","first-page":"14664","DOI":"10.1021\/acs.jmedchem.1c01196","volume":"64","author":"Z Wang","year":"2021","unstructured":"Wang Z, Cai J, Ren J, Chen Y, Wu Y, Cheng J, Jia K, Huang F, Cheng Z, Sheng T, Song S, Heng H, Zhu Y, Tang W, Li H, Lu T, Chen Y, Lu S (2021) Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations. J Med Chem 64(19):14664\u201314701. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01196","journal-title":"J Med Chem"},{"key":"771_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091586","volume":"17","author":"T Chatzilygeroudi","year":"2025","unstructured":"Chatzilygeroudi T, Karantanos T, Pappa V (2025) Unraveling venetoclax resistance: navigating the future of HMA\/venetoclax-refractory AML in the molecular era. Cancers 17:1586. https:\/\/doi.org\/10.3390\/cancers17091586","journal-title":"Cancers"},{"issue":"1","key":"771_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03513-4","volume":"9","author":"JX Cheng","year":"2018","unstructured":"Cheng JX, Chen L, Li Y, Cloe A, Yue M, Wei J, Watanabe KA, Shammo JM, Anastasi J, Shen QJ, Larson RA, He C, Le Beau MM, Vardiman JW (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9(1):1163. https:\/\/doi.org\/10.1038\/s41467-018-03513-4","journal-title":"Nat Commun"},{"issue":"12","key":"771_CR101","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/leu.2015.165","volume":"29","author":"CC Smith","year":"2015","unstructured":"Smith CC, Lin K, Stecula A, Sali A, Shah NP (2015) FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia 29(12):2390\u20132392. https:\/\/doi.org\/10.1038\/leu.2015.165","journal-title":"Leukemia"},{"key":"771_CR102","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-3969","volume":"82","author":"L Al Ashiri","year":"2022","unstructured":"Al Ashiri L, Moharram S, Purohit R, Kazi JU, R\u00f6nnstrand L (2022) Abstract 3969: Y842 mutations in the activation loop of FLT3 regulates drug response in FLT3-ITD positive acute myeloid leukemia. Cancer Res 82:3969. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-3969","journal-title":"Cancer Res"},{"key":"771_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.753276","volume":"8","author":"Y Liu","year":"2021","unstructured":"Liu Y, Chen Y, Huang S, Ma X, Huang X, Wang X, Zhou F (2021) Rapid and sensitive diagnosis of drug-resistant FLT3-F691L mutation by CRISPR detection. Front Mol Biosci 8:753276. https:\/\/doi.org\/10.3389\/fmolb.2021.753276","journal-title":"Front Mol Biosci"},{"issue":"8","key":"771_CR104","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.3324\/haematol.2022.282148","volume":"108","author":"GW Roloff","year":"2023","unstructured":"Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H et al (2023) Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica 108(8):2234\u20132239. https:\/\/doi.org\/10.3324\/haematol.2022.282148","journal-title":"Haematologica"},{"issue":"1","key":"771_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08263-x","volume":"10","author":"H Zhang","year":"2019","unstructured":"Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK et al (2019) Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun 10(1):244. https:\/\/doi.org\/10.1038\/s41467-018-08263-x","journal-title":"Nat Commun"},{"key":"771_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1072028","volume":"9","author":"SH Jang","year":"2022","unstructured":"Jang SH, Sivakumar D, Mudedla SK, Choi J, Lee S, Jeon M, Bvs SK et al (2022) PCW-A1001, AI-assisted de novo design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia. Front Mol Biosci 9:1072028. https:\/\/doi.org\/10.3389\/fmolb.2022.1072028","journal-title":"Front Mol Biosci"},{"issue":"3","key":"771_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e25369","volume":"10","author":"EY Abbasi","year":"2024","unstructured":"Abbasi EY, Deng Z, Ali Q, Khan A, Shaikh A, Reshan MSA, Sulaiman A, Alshahrani H (2024) A machine learning and deep learning-based integrated multi-omics technique for leukemia prediction. Heliyon 10(3):e25369. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25369","journal-title":"Heliyon"},{"issue":"1","key":"771_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-79799-w","volume":"14","author":"F Noor","year":"2024","unstructured":"Noor F, Junaid M, Almalki AH, Almaghrabi M, Ghazanfar S, Tahir Ul Qamar M (2024) Deep learning pipeline for accelerating virtual screening in drug discovery. Sci Rep 14(1):28321. https:\/\/doi.org\/10.1038\/s41598-024-79799-w","journal-title":"Sci Rep"},{"issue":"3","key":"771_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032026","volume":"24","author":"C Sarkar","year":"2023","unstructured":"Sarkar C, Das B, Rawat VS, Wahlang JB, Nongpiur A, Tiewsoh I, Lyngdoh NM, Das D, Bidarolli M, Sony HT (2023) Artificial intelligence and machine learning technology driven modern drug discovery and development. Int J Mol Sci 24(3):2026. https:\/\/doi.org\/10.3390\/ijms24032026","journal-title":"Int J Mol Sci"},{"issue":"1","key":"771_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01707-5","volume":"22","author":"JM Kelm","year":"2023","unstructured":"Kelm JM, Pandey DS, Malin E, Kansou H, Arora S, Kumar R, Gavande NS (2023) PROTAC\u2019ing oncoproteins: targeted protein degradation for cancer therapy. Mol Cancer 22(1):62. https:\/\/doi.org\/10.1186\/s12943-022-01707-5","journal-title":"Mol Cancer"},{"issue":"12","key":"771_CR111","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.tips.2024.10.006","volume":"45","author":"J Ge","year":"2024","unstructured":"Ge J, Hsieh CY, Fang M, Sun H, Hou T (2024) Development of PROTACs using computational approaches. Trends Pharmacol Sci 45(12):1162\u20131174. https:\/\/doi.org\/10.1016\/j.tips.2024.10.006","journal-title":"Trends Pharmacol Sci"},{"key":"771_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116717","volume":"277","author":"HM Hesham","year":"2024","unstructured":"Hesham HM, Dokla EME, Elrazaz EZ, Lasheen DS, Abou El Ella DA (2024) Flt3-PROTACs for combating AML resistance: analytical overview on chimeric agents developed, challenges, and future perspectives. Eur J Med Chem 277:116717. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116717","journal-title":"Eur J Med Chem"},{"issue":"5","key":"771_CR113","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41589-021-00742-5","volume":"17","author":"L Wang","year":"2021","unstructured":"Wang L, Shao X, Zhong T, Wu Y, Xu A, Sun X, Gao H, Liu Y, Lan T, Tong Y, Tao X, Du W, Wang W, Chen Y, Li T, Meng X, Deng H, Yang B, He Q, Ying M, Rao Y (2021) Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nat Chem Biol 17(5):567\u2013575. https:\/\/doi.org\/10.1038\/s41589-021-00742-5","journal-title":"Nat Chem Biol"},{"issue":"1","key":"771_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15384047.2022.2125748","volume":"23","author":"L Ma","year":"2022","unstructured":"Ma L, Wang J, Zhang Y, Fang F, Ling J, Chu X, Zhang Z, Tao Y, Li X, Tian Y, Li Z, Sang X, Zhang K, Lu L, Wan X, Chen Y, Yu J, Zhuo R, Wu S, Lu J, Pan J, Hu S (2022) BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes. Cancer Biol Ther 23(1):1\u201315. https:\/\/doi.org\/10.1080\/15384047.2022.2125748","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"771_CR115","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.3324\/haematol.2022.281915","volume":"108","author":"Y Jia","year":"2023","unstructured":"Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M (2023) Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 108(10):2626\u20132638. https:\/\/doi.org\/10.3324\/haematol.2022.281915","journal-title":"Haematologica"},{"issue":"22","key":"771_CR116","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70401","volume":"13","author":"NRBM Sahib","year":"2024","unstructured":"Sahib NRBM, Mohamed JS, Rashid MBMA, Jayalakshmi LYC, Chee YL, Fan BE, De Mel S, Ooi MGM, Jen WY, Chow EK (2024) A combinatorial functional precision medicine platform for rapid therapeutic response prediction in AML. Cancer Med 13(22):e70401. https:\/\/doi.org\/10.1002\/cam4.70401","journal-title":"Cancer Med"},{"key":"771_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107437","volume":"136","author":"I Didi","year":"2024","unstructured":"Didi I, Alliot JM, Dumas PY, Vergez F, Tavitian S, Largeaud L, Bidet A, Rieu JB, Luquet I, Lechevalier N, Delabesse E, Sarry A, De Grande AC, B\u00e9rard E, Pigneux A, R\u00e9cher C, Simoncini D, Bertoli S (2024) Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: a DATAML registry study. Leuk Res 136:107437. https:\/\/doi.org\/10.1016\/j.leukres.2024.107437","journal-title":"Leuk Res"},{"issue":"36","key":"771_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202506447","volume":"12","author":"Y Wang","year":"2025","unstructured":"Wang Y, Liu R, Zhang Y, Luo X, Yu C, Fang S, Tan N, Tang J (2025) A network-driven framework for drug response precision prediction of acute myeloid leukemia. Adv Sci 12(36):e06447. https:\/\/doi.org\/10.1002\/advs.202506447","journal-title":"Adv Sci"},{"issue":"8","key":"771_CR119","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/17460441.2019.1623202","volume":"14","author":"V Kairys","year":"2019","unstructured":"Kairys V, Baranauskiene L, Kazlauskiene M, Matulis D, Kazlauskas E (2019) Binding affinity in drug design: experimental and computational techniques. Expert Opin Drug Discov 14(8):755\u2013768. https:\/\/doi.org\/10.1080\/17460441.2019.1623202","journal-title":"Expert Opin Drug Discov"},{"issue":"12","key":"771_CR120","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1021\/acs.jcim.7b00564","volume":"57","author":"Z Cournia","year":"2017","unstructured":"Cournia Z, Allen B, Sherman W (2017) Relative binding free energy calculations in drug discovery: recent advances and practical considerations. J Chem Inf Model 57(12):2911\u20132937. https:\/\/doi.org\/10.1021\/acs.jcim.7b00564","journal-title":"J Chem Inf Model"},{"key":"771_CR121","doi-asserted-by":"crossref","unstructured":"Arora A, Kaur S, Singh A (2024) Challenges and emerging problems in CADD. In: Drug delivery systems using quantum computing. Wiley, pp 407\u2013441","DOI":"10.1002\/9781394159338.ch14"},{"key":"771_CR122","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/bs.apha.2025.02.002","volume":"103","author":"S Sur","year":"2025","unstructured":"Sur S, Nimesh H (2025) Challenges and limitations of computer-aided drug design. Adv Pharmacol 103:415\u2013428. https:\/\/doi.org\/10.1016\/bs.apha.2025.02.002","journal-title":"Adv Pharmacol"},{"key":"771_CR123","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","volume":"99","author":"SA Hollingsworth","year":"2018","unstructured":"Hollingsworth SA, Dror RO (2018) Molecular dynamics simulation for all. Neuron 99:1129\u20131143. https:\/\/doi.org\/10.1016\/j.neuron.2018.08.011","journal-title":"Neuron"},{"issue":"6","key":"771_CR124","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/jcc.23973","volume":"37","author":"GR Bowman","year":"2016","unstructured":"Bowman GR (2016) Accurately modeling nanosecond protein dynamics requires at least microseconds of simulation. J Comput Chem 37(6):558\u2013566. https:\/\/doi.org\/10.1002\/jcc.23973","journal-title":"J Comput Chem"},{"issue":"15","key":"771_CR125","doi-asserted-by":"publisher","first-page":"7167","DOI":"10.1021\/acs.jmedchem.6b00632","volume":"59","author":"L Mollica","year":"2016","unstructured":"Mollica L, Theret I, Antoine M, Perron-Sierra F, Charton Y, Fourquez JM, Wierzbicki M, Boutin JA, Ferry G, Decherchi S, Bottegoni G, Ducrot P, Cavalli A (2016) Molecular dynamics simulations and kinetic measurements to estimate and predict protein-ligand residence times. J Med Chem 59(15):7167\u20137176. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00632","journal-title":"J Med Chem"},{"issue":"23","key":"771_CR126","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.1021\/acs.jcim.2c01073","volume":"62","author":"D van Tilborg","year":"2022","unstructured":"van Tilborg D, Alenicheva A, Grisoni F (2022) Exposing the limitations of molecular machine learning with activity cliffs. J Chem Inf Model 62(23):5938\u20135951. https:\/\/doi.org\/10.1021\/acs.jcim.2c01073","journal-title":"J Chem Inf Model"},{"issue":"4","key":"771_CR127","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/cpt.3542","volume":"117","author":"D Wilczok","year":"2025","unstructured":"Wilczok D, Zhavoronkov A (2025) Progress, pitfalls, and impact of AI-driven clinical trials. Clin Pharmacol Ther 117(4):887\u2013890. https:\/\/doi.org\/10.1002\/cpt.3542","journal-title":"Clin Pharmacol Ther"},{"key":"771_CR128","unstructured":"Buvailo A, Kucheriavyi O biopharmatrend it\u2019s been a decade of AI in the drug discovery race. What\u2019s next? https:\/\/www.techlifesci.com\/p\/its-been-a-decade-of-ai-in-the-drug. Accessed 19 Jan 2026"},{"issue":"7","key":"771_CR129","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MWN (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110(7):2242\u20132249. https:\/\/doi.org\/10.1182\/blood-2007-03-066936","journal-title":"Blood"},{"key":"771_CR130","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/B978-0-12-814421-3.00021-X","volume-title":"Dosage form design parameters","author":"B Chandrasekaran","year":"2018","unstructured":"Chandrasekaran B, Abed SN, Al-Attraqchi O (2018) Chapter 21\u2014computer-aided prediction of pharmacokinetic (ADMET) properties. In: Tekade RK (ed) Dosage form design parameters. Academic Press, pp 731\u2013755"},{"key":"771_CR131","doi-asserted-by":"publisher","DOI":"10.1101\/2023.12.28.573531","author":"K Swanson","year":"2023","unstructured":"Swanson K, Walther P, Leitz J, Mukherjee S, Wu JC, Shivnaraine RV, Zou J (2023) ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. bioRxiv. https:\/\/doi.org\/10.1101\/2023.12.28.573531","journal-title":"bioRxiv"},{"issue":"7","key":"771_CR132","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1021\/acs.jcim.4c02122","volume":"65","author":"H Han","year":"2025","unstructured":"Han H, Shaker B, Lee JH, Choi S, Yoon S, Singh M, Basith S, Cui M, Ahn S, An J, Kang S, Yeom MS, Choi S (2025) Employing automated machine learning (AutoML) methods to facilitate the in silico ADMET properties prediction. J Chem Inf Model 65(7):3215\u20133225. https:\/\/doi.org\/10.1021\/acs.jcim.4c02122","journal-title":"J Chem Inf Model"},{"key":"771_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217427","author":"P Jin","year":"2024","unstructured":"Jin P, Shen J, Zhao M, Yu J, Jin W, Jiang G, Li Z, He M, Liu X, Wu S, Dong F, Cao Y, Zhu H, Li X, Wang X, Zhang Y, Jin Z, Li J, Wang K (2024) Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2024.217427","journal-title":"Cancer Lett"},{"issue":"1","key":"771_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13658-3","volume":"25","author":"X Bao","year":"2025","unstructured":"Bao X, Chen Y, Chang J, Du J, Yang C, Wu Y, Sha Y, Li M, Chen S, Yang M, Liu SB (2025) Machine learning-based bulk RNA analysis reveals a prognostic signature of 13 cell death patterns and potential therapeutic target of SMAD3 in acute myeloid leukemia. BMC Cancer 25(1):273. https:\/\/doi.org\/10.1186\/s12885-025-13658-3","journal-title":"BMC Cancer"},{"issue":"7999","key":"771_CR135","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/d41586-024-00392-2","volume":"626","author":"E Dolgin","year":"2024","unstructured":"Dolgin E (2024) The future of precision cancer therapy might be to try everything. Nature 626(7999):470\u2013473. https:\/\/doi.org\/10.1038\/d41586-024-00392-2","journal-title":"Nature"},{"issue":"3","key":"771_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pdig.0000187","volume":"2","author":"M Hehr","year":"2023","unstructured":"Hehr M, Sadafi A, Matek C, Lienemann P, Pohlkamp C, Haferlach T, Spiekermann K, Marr C (2023) Explainable AI identifies diagnostic cells of genetic AML subtypes. PLoS Digit Health 2(3):e0000187. https:\/\/doi.org\/10.1371\/journal.pdig.0000187","journal-title":"PLoS Digit Health"},{"issue":"6","key":"771_CR137","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/1878-0261.70000","volume":"19","author":"Y Song","year":"2025","unstructured":"Song Y, Wang Z, Zhang G, Hou J, Liu K, Wei S, Li Y, Zhou C, Lin D, Wang M, Wei H, Wang J, Cheng T, Mi Y (2025) Classification of acute myeloid leukemia based on multi-omics and prognosis prediction value. Mol Oncol 19(6):1836\u20131854. https:\/\/doi.org\/10.1002\/1878-0261.70000","journal-title":"Mol Oncol"},{"issue":"667","key":"771_CR138","doi-asserted-by":"publisher","first-page":"eabn7824","DOI":"10.1126\/scitranslmed.abn7824","volume":"14","author":"J Goh","year":"2022","unstructured":"Goh J, De Mel S, Hoppe MM, Mohd Abdul Rashid MB, Zhang XY, Jaynes P, Ka Yan Ng E, Rahmat NDB, Jayalakshmi LCX, Poon L, Chan E, Lee J, Chee YL, Koh LP, Tan LK, Soh TG et al (2022) An ex vivo platform to guide drug combination treatment in relapsed\/refractory lymphoma. Sci Transl Med 14(667):eabn7824. https:\/\/doi.org\/10.1126\/scitranslmed.abn7824","journal-title":"Sci Transl Med"},{"issue":"3","key":"771_CR139","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s43018-025-00917-2","volume":"6","author":"TG Chang","year":"2025","unstructured":"Chang TG, Park S, Sch\u00e4ffer AA, Jiang P, Ruppin E (2025) Hallmarks of artificial intelligence contributions to precision oncology. Nat Cancer 6(3):417\u2013431. https:\/\/doi.org\/10.1038\/s43018-025-00917-2","journal-title":"Nat Cancer"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00771-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-026-00771-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00771-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:08:00Z","timestamp":1772554080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-026-00771-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":139,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s10822-026-00771-z","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"72"}}